Renin-angiotensin system and atherosclerosis

Nephrology Dialysis Transplantation

Volumn 19, Issue 4, 2004, Pages 770-773

  Grote, Karsten ^a   Drexler, Helmut ^a   Schieffer, Bernhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Angiotensin II; AT1 receptor; Atherosclerosis; Inflammation; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CATHEPSIN G; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; IRBESARTAN; LOSARTAN; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PERINDOPRIL; RAMIPRIL; TELMISARTAN; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROSIS; CELL MIGRATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; EDITORIAL; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; LIPID METABOLISM; MICROALBUMINURIA; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIOSCLEROSIS; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 1842575825     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh030     Document Type: Editorial

References (29)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126
2. LaRosa JC. Atherosclerotic risk factors in cardiovascular disease. J Reprod Med 1986; 31: 906-912
3. Nickenig G. Central role of the AT(1)-receptor in atherosclerosis. J Hum Hypertens 2002; 16: S26-S33
4. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002: 89: 3A-9A
5. Jackson EK. Renin and angiotensin. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodmann & Gilman's The Pharmacological Basis ol Therapeutics, 10th edn. McGrawHill, New York; 2001: 809-841
6. Johnston CI, Risvanis J. Preclinical pharmacology of angiotensin II receptor antagonists: Update and outstanding issue. Am J Herpertens 1997; 10: 306-310
7. Müller DN, Luft FC. The renin-angiotensin system in the vessel wall. Basic Res Cardiol 1998; 93: 7-14
8. Tallant EA, Diz DI, Ferrario CM. Antiproliferative actions of angiotensin (1-7) in vascular smooth muscle. Hypertension 1999; 34: 950-957
9. Linz W, Wohlfart P, Schoelkens BA, Malinski T, Wiemer G. Interactions among ACE, kinins and NO. Cardiovasc Res 1999: 43: 549-561
10. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger Th. International Union of Pharmacology. XXIII. The angiotensin II receptor. Pharmacol Rev 2000; 52: 415-472
11. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995: 96: 2515-2520
12. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Cire Res 1994; 74: 1141-1148
13. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res 2000; 87: 1195-1201
14. Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation 1997; 96: 3264-3265
15. Chakraborti S, Chakraborti T. Oxidant-mediated activation of mitogen-activated protein kinases and nuclear transcription factors in the cardiovascular system: A brief overview. Cell Signal 1998; 10: 675-683
16. Tham DM, Martin-McNulty B. Wang YX et al. Angiotensin II is associated with activation of NF-κB-mediated genes and downregulation of PPARs. Physiol Genomics 2002; 11: 21-30
17. Pratt RE. Angiotensin II and the control of cardiovascular structure. J Am Soc Nephrol 1999; 11: 120-128
18. Keidar S, Kaplan M, Hoffman A, Aviram M. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis 1995; 115: 201-215
19. Morawietz H. Rueckschloss U, Niemann B et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999; 100: 899-902
20. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503
21. Brown NJ, Vaughan DE. Prothrombotic effects of angiotensin. Adv Intern Med 2000; 45: 419-429
22. Bernstein KE. Examining the renin-angiotensin system one hundred years after its discovery. Nephrologie 1998; 19: 391-395
23. Diet F, Pratt RE, Berry GJ. Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756-2767
24. Neri Serneri GG, Boddi M, Poggesi L et al. Activation of cardiac renin-angiotensin system in unstable angina. J Am Coll Cardiol 2001; 38: 49-55
25. Yusuf S. Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N Engl J Med 2000; 342: 145-153.
26. Fox KM for the EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788
27. Dahlof B, Devereux RB, Kjeldsen SE et al. for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003
28. Sica DA, Bakris GL. Type 2 diabetes: RENAAL and IDNT - the emergence of new treatment options. J Clin Hypertens 2002; 4: 52-57
29. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878